Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN) | Synapse
July 16, 2020Open Access
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Sorafenib maintenance therapy reduces the risk of relapse and death after HCT for FLT3-ITD-positive AML.